GLPwatch
Papers (10378)
Page 93 of 173, ranked by citation count.
- Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison.
- Exenatide prevents statin-related LDL receptor increase and improves insulin secretion in pancreatic beta cells (1.1E7) in a protein kinase A-dependent manner.
- Oral Semaglutide Reduces HbA<sub>1c</sub> and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses.
- The vascular impact of dapagliflozin, liraglutide, and atorvastatin alone or in combinations in type 2 diabetic rat model.
- Insulin and IGF-1 receptor autocrine loops are not required for Exendin-4 induced changes to pancreatic β-cell bioenergetic parameters and metabolism in BRIN-BD11 cells.
- Effect of once-weekly dulaglutide on renal function in patients with chronic kidney disease.
- A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
- Semaglutide use in people with obesity and type 2 diabetes from real-world utilization data: An analysis of the All of US Program.
- Patient factors associated with glucagonlike peptide 1 receptor agonist use with and without insulin.
- Minimal modeling of insulin secretion in the perfused rat pancreas: a drug effect case study.
- Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity.
- The effects of metformin, pioglitazone, exenatide and exercise on fatty liver in obese diabetic rats: the role of IRS-1 and SOCS-3 molecules.
- Exploring Hypoglycemic Ketoacidosis in Nondiabetic Patients on Tirzepatide: Is Starvation the Culprit?
- Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial.
- Use of glucagon-like-peptide 1 receptor agonist in the treatment of childhood obesity.
- Prediction of thyroid C-cell carcinogenicity after chronic administration of GLP1-R agonists in rodents.
- Perspectives on weight control in diabetes - Tirzepatide.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomized, placebo-controlled phase 2 study.
- Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial.
- Glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptor poly-agonists: a new era in obesity pharmacotherapy.
- <sup>68</sup>Ga-labelled-exendin-4: New GLP1R targeting agents for imaging pancreatic β-cell and insulinoma.
- Factors associated with gastrointestinal side effects after liraglutide treatment for type 2 diabetes.
- MiR-7, miR-9 and miR-375 contribute to effect of Exendin-4 on pancreatic β-cells in high-fat-diet-fed mice.
- Dulaglutide improves glucocorticoid-induced hyperglycemia in inpatient care and reduces dose and injection frequency of insulin.
- Liraglutide Effect on Ventricular Transient Outward K + Channel and Connexin-43 Protein Expression.
- No clinical harm from a massive exenatide overdose: a short report.
- Oral self-nanoemulsifying formulation of GLP-1 agonist peptide exendin-4: development, characterization and permeability assesment on Caco-2 cell monolayer.
- Effect of preoperative liraglutide 3.0 mg on incidence of intraoperative adhesions in laparoscopic sleeve gastrectomy.
- Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study.
- The protective effects of GLP-1 receptor agonist lixisenatide on oxygen-glucose deprivation/reperfusion (OGD/R)-induced deregulation of endothelial tube formation.
- Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia.
- Effect of Liraglutide Treatment on Whole-body Glucose Fluxes in C-peptide-Positive Type 1 Diabetes During Hypoglycemia.
- Partial blockade of Kv2.1 channel potentiates GLP-1's insulinotropic effects in islets and reduces its dose required for improving glucose tolerance in type 2 diabetic male mice.
- Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?
- The effect of exenatide (a GLP-1 analog) and sitagliptin (a DPP-4 inhibitor) on plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and concentration in normal and fructose-fed rats.
- Design of self-emulsifying oral delivery systems for semaglutide: reverse micelles versus hydrophobic ion pairs.
- Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit.
- Liraglutide protects from renal damage via Akt-mTOR pathway in rats with diabetic kidney disease.
- Weight and Glucose Reduction Observed with a Combination of Nutritional Agents in Rodent Models Does Not Translate to Humans in a Randomized Clinical Trial with Healthy Volunteers and Subjects with Type 2 Diabetes.
- Sustained Weight Loss With Combined LEAP2 and Semaglutide Treatment in Mice.
- Weight loss breaks the bond between nonalcoholic fatty liver disease and cardiovascular diseases: A clinical and epidemiological perspective.
- Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study.
- Impact of ADA Guidelines and Medication Shortage on GLP-1 Receptor Agonists Prescribing Trends in the UK: A Time-Series Analysis with Country-Specific Insights.
- Investigation of transport mechanism of exendin-4 across Madin Darby canine kidney cell monolayers.
- Liraglutide improves follicle development in polycystic ovary syndrome by inhibiting CXCL10 secretion.
- Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi.
- GLP-1 receptor agonist improves metabolic disease in a pre-clinical model of lipodystrophy.
- Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide in people with type 2 diabetes or obesity with a history of acute pancreatitis: A propensity matched global federated TriNetX database-based retrospective cohort study.
- Glucagon-like peptide-1 agonists in cardiovascular diseases: a bibliometric analysis from inception to 2023.
- Activation of glucagon-like peptide-1 receptors reduces the acquisition of aggression-like behaviors in male mice.
- The Tirzepatide Drop: Beware of Slimmer's Paralysis.
- [The effects of liraglutide on body composition and muscle strength in adult obese patients with type 2 diabetes mellitus].
- The Effect of Liraglutide on Axon Regeneration and Functional Recovery after Peripheral Nerve Lesion.
- Role of Glucagon-Like Peptide-1 on Amyloid, Tau, and α-Synuclein: Target Engagement and Rationale for the Development in Neurodegenerative Disorders.
- Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome.
- A Case Report of Systemic Allergic Reaction to the Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide.
- Exendin-4 Improves Cognitive Function of Diabetic Mice via Increasing Brain Insulin Synthesis.
- Novel insights into the augmented effect of curcumin and liraglutide in ameliorating cisplatin-induced nephrotoxicity in rats: Effects on oxidative stress, inflammation, apoptosis and pyroptosis via GSK-3β.
- Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
- Incretin concepts.